|
|
| Line 1: |
Line 1: |
| {{drugbox
| | #REDIRECT [[Enalapril]] |
| | IUPAC_name = 1-[2-(1-ethoxycarbonyl-3-phenyl-propyl) aminopropanoyl] pyrrolidine-2-carboxylic acid. <BR><BR>(Diagrams above are enalpril and enalaprilat, respectively. Data below refers to enalapril unless indicated)
| |
| | image = enalapril.png
| |
| | image2 = enalaprilat.png
| |
| | width = 200
| |
| | CAS_number = 75847-73-3
| |
| | ATC_prefix = C09
| |
| | ATC_suffix = AA02
| |
| | ATC_supplemental =
| |
| | PubChem = 5362032
| |
| | DrugBank = APRD00510
| |
| | C=20 | H=28 | N=2 | O=5
| |
| | molecular_weight = 376.447 g/mol
| |
| | bioavailability = 60% (oral)
| |
| | protein_bound =
| |
| | metabolism = hepatic (to enalaprilat)
| |
| | elimination_half-life = 11 hours (enalaprilat)
| |
| | pregnancy_AU = 5
| |
| | pregnancy_US =
| |
| | pregnancy_category =
| |
| | legal_status = Rx-only
| |
| | routes_of_administration =
| |
| | excretion = renal
| |
| }}
| |
| {{CMG}}
| |
| | |
| | |
| | |
| ==[[Enalapril (patient information)|For patient information, click here]]==
| |
| | |
| '''Enalapril''' is an [[ACE inhibitor|angiotensin converting enzyme (ACE) inhibitor]] used in the treatment of [[hypertension]] and some types of chronic [[heart failure]]. Enalapril was the first member of the group of ACE inhibitors known as the dicarboxylate-containing ACE inhibitors. It is marketed by [[Merck & Co.]] (Merck, Sharp & Dohme) under the trade names, ''Renitec®'' and ''Vasotec®''.
| |
| | |
| ==Development==
| |
| Enalapril was developed by researchers at [[Merck & Co.]] as part of their efforts to develop novel treatments for hypertension by modulating the [[renin-angiotensin system|renin-angiotensin-aldosterone]] (RAS) system.
| |
| | |
| The success of Squibb in developing the first inhibitor, [[captopril]], provided a major impetus for Merck's research laboratories to develop a competing product. Captopril was not without its problems, however, as it was believed (and shown to be true) that the [[sulfhydryl]]-[[moiety]] of captopril was responsible for such adverse effects as metallic taste.
| |
| | |
| ==Enalaprilat==
| |
| '''Enalaprilat''', the first dicarboxylate-containing ACE inhibitor, was developed partly to overcome these limitations of captopril. The sulfhydryl-moiety was replaced by a carboxylate-moiety, but additional modifications were required in its structure-based design to achieve a similar potency to captopril.
| |
| | |
| Enalaprilat itself, however, was not without its problems. The consequence of the structural modifications was that it proved to be have unfavourable ionisation characteristics to allow sufficient potency for oral administration (in tablets). Thus enalaprilat was only suitable for [[intravenous]] administration. This was overcome by the researchers at Merck by the [[esterification]] of enalaprilat with ethanol to produce '''enalapril'''.
| |
| | |
| As a [[prodrug]], enalapril is metabolised ''in vivo'' to the active form enalaprilat by various [[esterase]]s. Peak plasma enalaprilat concentrations occur 2 to 4 hours after oral enalapril administration. Elimination thereafter is biphasic, with an initial phase which reflects renal filtration (elimination half-life 2 to 6 hours) and a subsequent prolonged phase (elimination half-life 36 hours), the latter representing equilibration of drug from tissue distribution sites.
| |
| | |
| The prolonged phase does not contribute to drug accumulation on repeated administration but is thought to be of pharmacological significance in mediating drug effects. Renal impairment [particularly creatinine clearance < 20 ml/min (< 1.2 L/h)] results in significant accumulation of enalaprilat and necessitates dosage reduction. Accumulation is probably the cause of reduced elimination in healthy elderly individuals and in patients with concomitant diabetes, hypertension and heart failure.
| |
| | |
| == A prototype for others ==
| |
| Most importantly, perhaps, the [[QSAR]]-based modifications in structure serendipitously led to an improved understanding of the structure of ACE which aided in the development of subsequent [[carboxylate]]-containing ACE inhibitors.
| |
| | |
| {{ACE inhibitors}}
| |
| | |
| [[Category:ACE inhibitors]]
| |
| [[Category:Prodrugs]]
| |
| [[Category:Drugs]]
| |
| | |
| [[hr:Enalapril]]
| |
| [[ja:エナラプリル]]
| |
| [[nn:Enalapril]]
| |
| [[pt:Enalapril]]
| |
| [[th:อีนาลาพริล]]
| |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |